Kathrin Bernt
Pediatrics / Pediatric Hematology-Oncology
Credentials: · · · ·
History
Medical Genetics
- 2006–2009
- 2004–2006
2003–2004- 1999–2000
Charite Humboldt University
- 1995–1999
Research
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
Cancer Cell · 2011 · 756 citations
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L
Cancer Cell · 2011 · First of 14 authors · 745 citations
Chromatin-modifying enzymes as modulators of reprogramming
Nature · 2012 · 525 citations
14 papers
11 papers
9 papers
9 papers · 2 as a fellow
- TN
9 papers
7 papers · 5 as a fellow
7 papers · 1 as a fellow
7 papers
Grants
- 2022–2027
A Stalled Chromatin Regulatory Network That Mediates the Oncogenic Activity of Meningioma-1
National Cancer Institute · R01
Contact PI · $2.1M · Children's Hosp of Philadelphia
- 2022–2027
IDP Mediated Transcriptional Stabilization as a Cause of AML
National Cancer Institute · R01
Contact PI · $1.2M · Children's Hosp of Philadelphia
- 2020–2022
Center for Developmental Mapping of Heart and Bone Tissues
National Heart, Lung, and Blood Institute · U54
PI · $1M · Children's Hosp of Philadelphia
- 2015–2021
The Role of H3K79 Methylation in IDH-Mutant Leukemia
National Cancer Institute · R01
Contact PI · $2.2M · Children's Hosp of Philadelphia
Clinical trials
- 2025–2028
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)